Physician profile
Mark D Akin
NPI 1871512475
$9,947.69
in general payments reported to CMS, 2019-2025
47 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $1,908 · 2021: $799 · 2022: $1,473 · 2023: $1,054 · 2024: $2,359 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,938.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Asensus Surgical, INC. | $1,442.87 | 2019-2020 | |
| Abbvie INC. | $899.64 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Dysis Medical, INC. | $553.97 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $550.73 | 2023-2025 | Gemtesa, Myfembree |
| Coloplast Corp | $451.89 | 2023-2025 | Altis |
| Therapeuticsmd, INC. | $341.61 | 2019-2022 | |
| Shield Therapeutics INC | $304.18 | 2024-2025 | |
| Astellas Pharma US INC | $296.77 | 2019-2025 | Veozah |
| Medtronic, INC. | $275.28 | 2021-2022 | |
| Lupin INC. | $254.60 | 2019-2020 | |
| Minerva Surgical, INC | $218.25 | 2022 | |
| Hologic Sales and Service, LLC | $200.57 | 2019-2025 | Myosure Tissue Removal Device, Aptima |
| Axonics, INC. | $196.53 | 2022-2023 | Axonics |
| Daiichi Sankyo INC. | $183.70 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $180.77 | 2024-2025 | Zurzuvae |
| Covidien Lp | $161.76 | 2020 | |
| Innovation Technologies INC | $131.75 | 2024 | Irrisept |
| Pacira Pharmaceuticals Incorporated | $121.84 | 2024 | Exparel |
| Olympus America INC. | $121.23 | 2019 | |
| Exeltis, USA INC. | $111.78 | 2022-2024 | Slynd, Nuvessa |
| Teleflex LLC | $104.99 | 2024 | Urolift |
| Procept Biorobotics Corporation | $101.13 | 2024 | Aquabeam System |
| Evofem Biosciences, INC. | $96.06 | 2021-2024 | Phexxi |
| Lilly USA, LLC | $76.63 | 2024 | Zepbound |
| Mayne Pharma Commercial LLC | $68.47 | 2025 | |
| Avion Pharmaceuticals | $68.05 | 2020-2023 | Balcoltra |
| Currax Pharmaceuticals LLC | $63.39 | 2022-2024 | Contrave |
| Ethicon US, LLC | $49.35 | 2025 | Ethicon, Vistaseal |
| Ibsa Pharma INC. | $46.81 | 2021-2025 | Tirosint, Licart, Flector |
| Exact Sciences Corporation | $45.35 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $39.60 | 2024 | |
| Boston Scientific Corporation | $36.47 | 2025 | Axonics |
| Organon LLC | $31.38 | 2024 | |
| Amgen INC. | $28.04 | 2019 | |
| Aspira Women'S Health INC | $25.81 | 2024 | Ova1 |
| Srs Medical Systems, INC. | $24.04 | 2024 | Urocuff-Dc Disposable, Single, Ct3000 Pro Base Unit |
| Myovant Sciences INC. | $20.87 | 2022 | |
| Coopersurgical, INC. | $19.65 | 2024 | Paragard T 380a |
| Agile Therapeutics, INC. | $19.00 | 2021 | |
| Millicent US INC | $15.65 | 2024 | Intrarosa |
| Kci USA, INC. | $15.17 | 2021 | |
| Merck Sharp & Dohme LLC | $14.06 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Akin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.